Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) Shares Outstanding (Diluted Average) (2016 - 2025)

Capricor Therapeutics (CAPR) has 9 years of Shares Outstanding (Diluted Average) data on record, last reported at $45.7 million in Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) rose 38.07% year-over-year to $45.7 million; the TTM value through Sep 2025 reached $45.7 million, up 38.07%, while the annual FY2024 figure was $35.2 million, 31.52% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $45.7 million in Q3 2025 per CAPR's latest filing, roughly flat from $45.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $45.7 million in Q3 2025 and bottomed at $22.2 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $29.5 million, with a median of $25.3 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Diluted Average): surged 109.87% in 2021, then rose 3.97% in 2023.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $23.1 million in 2021, then increased by 6.34% to $24.6 million in 2022, then grew by 9.06% to $26.8 million in 2023, then skyrocketed by 31.52% to $35.2 million in 2024, then increased by 29.73% to $45.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $45.7 million in Q3 2025, $45.7 million in Q2 2025, and $45.6 million in Q1 2025.